Offer - Urjas Oil for just ₹ 1 X
Rapilif D 8 New Capsule is a commercial drug that is prescribed in the form of Capsule. Other than this, Rapilif D 8 New Capsule has some other therapeutic uses, which have been discussed ahead.
Medical history of the patient along with age and gender determines the dosage of Rapilif D 8 New Capsule. Individual symptoms and route of administration also determines the right dosage. For detailed information on this, read through the dosage section.
Apart from the aforementioned side effects, Rapilif D 8 New Capsule can also lead to other problems, which have been listed below. These side effects of Rapilif D 8 New Capsule are usually temporary and subside with the completion of treatment. If, however, they worsen or do not go away, please speak with your physician.
Rapilif D 8 New Capsule's effect during pregnancy is Severe and Severe while nursing. It is important to know if Rapilif D 8 New Capsule has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Rapilif D 8 New Capsule related warnings section.
Rapilif D 8 New Capsule can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Rapilif D 8 New Capsule in conditions like Kidney Disease, Liver Disease. Other contraindications of Rapilif D 8 New Capsule have been discussed in the sections ahead.
Additionally, Rapilif D 8 New Capsule may also adversely react with other medicines. See below for a complete list.
In addition to these precautions, you may also note that Rapilif D 8 New Capsule is safe while driving, and is is addictive in nature.
Rapilif D 8 New Capsule is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult(Male) |
|
Geriatric |
|
Is the use of Rapilif D 8 New Capsule safe for pregnant women?
Rapilif D should not be taken during pregnancy, or should only be taken on the advice of a doctor as it may have severe side effects.
Is the use of Rapilif D 8 New Capsule safe during breastfeeding?
Rapilif D may cause serious side effects in breastfeeding women, so do not take this drug without doctor's advice.
What is the effect of Rapilif D 8 New Capsule on the Kidneys?
Using Rapilif D does not have any harmful effects on kidneys.
What is the effect of Rapilif D 8 New Capsule on the Liver?
There may be an adverse effect on the liver after taking Rapilif D. If you observe any side effects on your body then stop taking this drug. Take this medicine again only if your doctor advises you to do so.
What is the effect of Rapilif D 8 New Capsule on the Heart?
Rapilif D is completely safe for the heart.
Rapilif D 8 New Capsule should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Rapilif D 8 New Capsule unless your doctor advises you to do so -
Is this Rapilif D 8 New Capsule habit forming or addictive?
Rapilif D 8 New Capsule does not cause addiction.
Interaction between Food and Rapilif D 8 New Capsule
Due to a lack of research, nothing can be said about the consequences of taking Rapilif D 8 New Capsule together with food.
Interaction between Alcohol and Rapilif D 8 New Capsule
Due to lack of research, nothing can be said about side effects of consuming alcohol while taking Rapilif D 8 New Capsule.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Rapaflo® (silodosin)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1137-1138
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 476-477
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 303
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Avodart® (dutasteride)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Jalyn (dutasteride and tamsulosin hydrochloride)